Statistics for Lyell Immunopharma, (id:7953 LYEL)

Valuation metrics

Market cap

265.26M

Enterprise value

-126,038,384.00

Trailing P/E (ttm)

-1.02

Forward P/E

-1.13

PEG ratio

-1.13

Price/Sales (ttm)

4.21K

Price/Book (mrq)

0.46

Enterprise Value/Revenue

-2,000.61

Enterprise Value/EBITDA

0.64

Overview

Shares outstanding

279.22M

Float

203.60M

Shares short

11.14M

% Held by insiders

0.14%

% Held by institutions

0.62%

Average volume (10 days)

1.38M

Average volume (90 days)

Price summary

52-Week low

0.85

52-Week high

3.26

52-Week change

-65.26%

Beta

-0.48

50-Day moving average

1.20

200-Day moving average

1.83

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-148,544.13%

Operational effectiveness

Return on assets

-19.12%

Return on equity

-33.22%

Income statement

Revenue (ttm)

0.00

Revenue per share (ttm)

0.00

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-196,600,000.00

Net income to common (ttm)

-203,988,992.00

Diluted EPS (ttm)

-0.79

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

440.55M

Total cash per share (mrq)

1.58

Total debt (mrq)

58.58M

Total Debt/Equity (mrq)

11.04

Current ratio (mrq)

1.34K%

Book value per share (mrq)

2.07

Cash flow

Cash flow statement

-155,787,008.00

Levered free cash flow (LFCF)

-83,122,752.00